Cargando…
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
CD47 is an immune checkpoint molecule that downregulates key aspects of both the innate and adaptive anti-tumor immune response via its counter receptor SIRPα, and it is expressed at high levels in a wide variety of tumor types. This has led to the development of biologics that inhibit SIRPα engagem...
Autores principales: | Miller, Thomas W., Amason, Joshua D., Garcin, Elsa D., Lamy, Laurence, Dranchak, Patricia K., Macarthur, Ryan, Braisted, John, Rubin, Jeffrey S., Burgess, Teresa L., Farrell, Catherine L., Roberts, David D., Inglese, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611588/ https://www.ncbi.nlm.nih.gov/pubmed/31276567 http://dx.doi.org/10.1371/journal.pone.0218897 |
Ejemplares similares
-
A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology
por: Burgess, Teresa L., et al.
Publicado: (2020) -
qHTSWaterfall: 3-dimensional visualization software for quantitative high-throughput screening (qHTS) data
por: Queme, Bryan, et al.
Publicado: (2023) -
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology
por: Dranchak, Patricia K., et al.
Publicado: (2023) -
CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022) -
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)